AU5503899A - Antiviral and antiretroviral radioimmunomedicaments based on alpha-emitters and beta-emitters - Google Patents

Antiviral and antiretroviral radioimmunomedicaments based on alpha-emitters and beta-emitters

Info

Publication number
AU5503899A
AU5503899A AU55038/99A AU5503899A AU5503899A AU 5503899 A AU5503899 A AU 5503899A AU 55038/99 A AU55038/99 A AU 55038/99A AU 5503899 A AU5503899 A AU 5503899A AU 5503899 A AU5503899 A AU 5503899A
Authority
AU
Australia
Prior art keywords
virus
fragment
emitters
hiv
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55038/99A
Inventor
Wolfgang Bergter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998128732 external-priority patent/DE19828732A1/en
Application filed by Individual filed Critical Individual
Publication of AU5503899A publication Critical patent/AU5503899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1006—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against or targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a pharmaceutical preparation comprising a radioimmunological conjugate (RIK) for in-vivo elimination of virus-replicating cells in HIV-1, HIV-2, HIV-3, HTLV-1, HTLV-2, HBV, HCV, HDV, CMV, EBV, HHV8 infections and in other chronic virus infections. The radioimmunological conjugate is characterized in that it contains, as immunologically effective constituents; d) a monoclonal antibody or the antigen-binding fragment thereof against a viral or virus-induced antigen expressed on the plasma membrane of virus-infected cells, or; e) a receptor molecule or the fragment thereof with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells; or f) a fragment of the cellular receptor molecule, said fragment being modified by mutagenesis, with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells. Said conjugate is also characterized in that it contains d) an alpha emitter or a beta emitter as a radioactive constituent. The inventive pharmaceutical preparation also optionally comprises a pharmaceutical carrier and/or adjuvant.
AU55038/99A 1998-06-29 1999-06-29 Antiviral and antiretroviral radioimmunomedicaments based on alpha-emitters and beta-emitters Abandoned AU5503899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1998128732 DE19828732A1 (en) 1998-03-08 1998-06-29 Antiviral and anti-retroviral radio-immuno conjugates, for the treatment of viral infections
DE19828732 1998-06-29
PCT/DE1999/001894 WO2000000223A2 (en) 1998-06-29 1999-06-29 ANTIVIRAL AND ANTIRETROVIRAL RADIOIMMUNOMEDICAMENTS BASED ON α-EMITTERS AND β-EMITTERS

Publications (1)

Publication Number Publication Date
AU5503899A true AU5503899A (en) 2000-01-17

Family

ID=7872232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55038/99A Abandoned AU5503899A (en) 1998-06-29 1999-06-29 Antiviral and antiretroviral radioimmunomedicaments based on alpha-emitters and beta-emitters

Country Status (7)

Country Link
EP (1) EP1091763B1 (en)
JP (1) JP2002519334A (en)
AT (1) ATE249846T1 (en)
AU (1) AU5503899A (en)
DE (1) DE59907027D1 (en)
ES (1) ES2212607T3 (en)
WO (1) WO2000000223A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
PE20141434A1 (en) 2008-07-16 2014-10-22 Inst Research In Biomedicine NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
CN106139150B (en) * 2015-04-10 2019-10-08 复旦大学 A kind for the treatment of AIDS vaccine composition and its application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339775C (en) * 1988-06-10 1998-03-24 Shuzo Matsushita Antibody 0.5b to hiv-i gp 120 modified with toxic substance
CA1339415C (en) * 1989-08-24 1997-09-02 Milton David Goldenberg Detection and treatment of infections with immunoconjugates
DE4025499A1 (en) * 1990-08-11 1992-02-13 Sandoz Ag USE OF THE ANTIKOERPER BR55-2, DERIVATIVES, CONJUGATES AND FRAGMENTS FOR THE TREATMENT OF HIV INFECTIONS
JPH08502260A (en) * 1992-09-30 1996-03-12 ザ スクリップス リサーチ インスティテュート Human neutralizing monoclonal antibody against human immunodeficiency virus
DE19809785C2 (en) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmune drug for the treatment of HIV-1 infection

Also Published As

Publication number Publication date
WO2000000223A2 (en) 2000-01-06
WO2000000223A3 (en) 2000-02-17
ES2212607T3 (en) 2004-07-16
ATE249846T1 (en) 2003-10-15
DE59907027D1 (en) 2003-10-23
EP1091763A2 (en) 2001-04-18
EP1091763B1 (en) 2003-09-17
JP2002519334A (en) 2002-07-02

Similar Documents

Publication Publication Date Title
Yan et al. Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model
Scharf et al. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1
Divano et al. Lichen planus, liver kidney microsomal (LKM1) antibodies and hepatitis C virus antibodies
FI941199A0 (en) Immunoreactive hepatitis C virus polypeptide compositions
DE69721713D1 (en) ANTI-HUMAN MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUS SURFACES (HBVSAG)
DK0676467T3 (en) European vaccine strains of the porcine reproductive respiratory syndrome virus (PRRSV)
EP1018344A3 (en) HLA-restricted hepatitis B virus CTL epitopes
DK0522030T3 (en) Hepatitis B vaccine
WO1992017493A3 (en) Peptides and mixtures thereof for detecting antibodies to hepatitis c virus (hcv)
JP2001527029A5 (en)
WO1999050301A3 (en) Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of hcv viral antigen in host tissue
WO2003095968A2 (en) Method for simultaneously detecting an antigen and an antibody of an infectious microorganism
DK0480949T3 (en) Preparation of viruses and purification of viral envelope proteins for vaccine use
WO2002038793A3 (en) Hepatitis c virus constructs characterized by high efficiency replication
AU5503899A (en) Antiviral and antiretroviral radioimmunomedicaments based on alpha-emitters and beta-emitters
AU4195696A (en) Hepatitis e virus antigens and uses therefor
Cann et al. Detection of antibodies to hepatitis E virus in patients with autoimmune chronic active hepatitis and primary biliary cirrhosis
Rollag et al. Viral safety of blood derivatives by immune neutralization
DK1002092T3 (en) Mimotopes of hypervariable region 1 of the E2 glycoprotein from HCV and applications thereof
FR2815634B1 (en) MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUSES
CA2412460A1 (en) Human monoclonal antibody against hepatitis c virus e2 glycoprotein
WO1999055385A3 (en) Radioimmunopharmaca for treating hepatitis c
DK0599913T3 (en) Monoclonal antibodies against putative hepatitis C virus NS5 proteins and methods of use of the same
JP2002519334A5 (en)
KR100871455B1 (en) Natural antibodies active against HIV virus

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase